Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial
Journal of the European Academy of Dermatology and Venereology · 01.06.2026
DOI: 10.1111/jdv.70524 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 01.06.2026. Verfasst von Ruggero Cascio Ingurgio und 16 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Roche.
Abstract (Originalsprache)
Background
Isotretinoin is the most effective treatment for severe acne, but optimal cumulative dosing remains debated. While 120 mg/kg is standard, some advocate higher doses or prolonged treatment to reduce relapse.
Objectives
To compare acne outcomes between 120 and 150 mg/kg cumulative isotretinoin dosing and to evaluate 12‐month relapse and scarring.
Methods
In this single‐centre, randomized single‐blind trial, with blinded outcomes assessment, patients with moderate‐to‐severe cystic acne were allocated to cumulative isotretinoin doses of 120 or 150 mg/kg. Primary outcomes were changes in total lesion count and acne severity grade (1–8 scale) from baseline to mid‐treatment and end of treatment; secondary outcomes included 12‐month acne relapse and scarring.
Results
Both cumulative dose groups showed comparable improvements in acne severity and lesion counts from baseline to treatment completion, with no significant differences between groups (all p > 0.20). Scarring did not worsen over the course of treatment. At 12 months after treatment discontinuation, relapse rates were similar between groups: 26.7% in the 120 mg/kg group and 32.3% in the 150 mg/kg group ( p = 0.619). Adverse events were mild and comparable.
Limitations
Single‐centre design and retrospective trial registration.
Conclusions
Increasing dosing to 150 mg/kg provides no benefit. Extended therapy does not reduce relapse, supporting 120 mg/kg as optimal. Persistent acne required longer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Dermatology Consultants, Woodbury, Minnesota, USA.
- Minneapolis VA Medical Center, Minneapolis, Minnesota, USA.
- Department of Dermatology, Children's Hospital, Northwestern University, Chicago, Illinois, USA.
- Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
ORCID-Profile: Ruggero Cascio Ingurgio, Dedee F Murrell
Förderung
- Roche
Zitieren
APA
Cascio Ingurgio, R., Alfano, A., Costanzo, A., Cronk, J. S., Cummins, R., Daniel, B. S., Koszegi, B. J., Martin, L. K., Mendoza, C. G., Ramirez-Quizon, M., Rhodes, L. M., Rishel, H. I., Rubin, A. I., Satgé, F., Venugopal, S., Wilson, A., & Murrell, D. F. (2026). Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70524
Vancouver
Cascio Ingurgio R, Alfano A, Costanzo A, Cronk JS, Cummins R, Daniel BS, et al. Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70524
BibTeX
@article{CascioIngurgio2026,
author = {Cascio Ingurgio, Ruggero and Alfano, Angela and Costanzo, Antonio and Cronk, Julie S and Cummins, Rebecca and Daniel, Benjamin S and Koszegi, Ben J and Martin, Linda K and Mendoza, Clarisse G and Ramirez-Quizon, Mae and Rhodes, Lesley M and Rishel, Heather I and Rubin, Adam I and Satgé, Fanny and Venugopal, Supriya and Wilson, Anna and Murrell, Dedee F},
title = {Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
doi = {10.1111/jdv.70524}
}
EUVIMED